XMax Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that XMax Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $12.74M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $12.56M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $11.35M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $21.98M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $81.18M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $106.49M | Apr 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.72M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $9.69M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $11.09M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.74M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $12.56M | Apr 17, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $106.49M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $92.65M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $89.94M | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | $98.71M | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | $78.36M | Mar 26, 2015 |
| FY2013 | Dec 31, 2012 | $66.30M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $43.16M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $28.82M | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.25M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.78M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.52M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($19.89M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $1.29M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $15.36M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $20.42M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $13.52M | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.42M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($5.56M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($7.72M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.10M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($19.96M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($26.08M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($8.60M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $5.30M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.76M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.12M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.93M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($5.36M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($6.42M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.22M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($3.86M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($26.30M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($5.80M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $4.83M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $6.80M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($766.1K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $2.00M | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | $3.12M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $10.9K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $110.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $33.7K | Apr 8, 2022 |
| FY2015 | Dec 31, 2015 | $1.07M | Mar 28, 2016 |
| FY2015 | Dec 31, 2014 | $1.25M | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | $426.7K | Mar 26, 2015 |
| FY2013 | Dec 31, 2012 | $497.9K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $164.7K | Apr 1, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($445.8K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.39M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.37M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($4.78M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($2.08M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $14.89M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($6.88M) | May 26, 2020 |
| FY2018 | Dec 31, 2017 | ($1.31M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($6.42M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $14.1K | Apr 15, 2026 |
| FY2022 | Dec 31, 2022 | $8.8K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $110.5K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $365.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $25.9K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $27.5K | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $26.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $13.5K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | $1.62M | Mar 28, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.55M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $9.92M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $6.24M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.53M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $29.53M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $46.48M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $71.56M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $90.09M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $79.86M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $77.04M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.59M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.79M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.92M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $6.09M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.55M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $5.51M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $15.18M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $11.41M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $13.78M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.96M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.12M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $496.4K | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $6.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $23.44M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $40.93M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $66.05M | Apr 8, 2022 |
| FY2020 | Dec 31, 2018 | $74.91M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $68.45M | May 26, 2020 |
| FY2018 | Dec 31, 2016 | $63.27M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $218.6K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $218.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $218.6K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $218.6K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $218.6K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $218.6K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $218.6K | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $218.6K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $218.6K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $218.6K | Apr 14, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($53.41M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($49.99M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($44.43M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($36.71M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($19.60M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $351.4K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $26.43M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $35.03M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $29.73M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $26.35M | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.71M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $161.9K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $369.1K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.37M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $6.28M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.74M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $7.42M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $243.6K | May 26, 2020 |
| FY2018 | Dec 31, 2017 | $5.72M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $2.59M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Apr 17, 2023 |
| FY2020 | Dec 31, 2020 | (4) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 26, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Apr 15, 2024 |
| FY2020 | Dec 31, 2020 | (4) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 26, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 14, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.89M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 7.30M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 1.92M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.43M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 6.84M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 5.60M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | 5.74M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 5.71M | May 26, 2020 |
| FY2018 | Dec 31, 2017 | 28.19M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 27.31M | Mar 29, 2018 |